A clinical trial will be conducted so that Celltrion can alternatively prescribe CT-P17 (Yuflyma), an autoimmune disease treatment developed by itself, with the original Humira. Celltrion announced on the 1st that it recently submitted a global phase 3 to the FDA to secure interchangeability between CT-P17 and Humira. If it is designated as an interchangeable biosimilar, it can be prescribed by replacing the original at a pharmacy without intervention by a doctor.

Phase 3 is conducted in 366 patients with plaque psoriasis. Pharmacokinetics, efficacy, and safety will be compared and verified between the group that took multiple intersections between Yuflyma and Humira and the group that administered Humi